Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) - Papp, K A; Langley, R G; Lebwohl, M (Lancet (London, England), 2008)
et al.